Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PTK2B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PTK2B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PTK2B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PTK2B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PTK2B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PTK2B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PTK2B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:20004013 | Oral cavity | OSCC | regulation of lymphocyte migration | 34/7305 | 61/18723 | 5.90e-03 | 2.25e-02 | 34 |
GO:00509204 | Oral cavity | OSCC | regulation of chemotaxis | 105/7305 | 223/18723 | 8.27e-03 | 3.01e-02 | 105 |
GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
GO:19055213 | Oral cavity | OSCC | regulation of macrophage migration | 24/7305 | 41/18723 | 8.81e-03 | 3.19e-02 | 24 |
GO:00435062 | Oral cavity | OSCC | regulation of JUN kinase activity | 32/7305 | 58/18723 | 9.08e-03 | 3.26e-02 | 32 |
GO:20002496 | Oral cavity | OSCC | regulation of actin cytoskeleton reorganization | 23/7305 | 39/18723 | 9.09e-03 | 3.26e-02 | 23 |
GO:200105715 | Oral cavity | OSCC | reactive nitrogen species metabolic process | 43/7305 | 82/18723 | 9.20e-03 | 3.30e-02 | 43 |
GO:00487713 | Oral cavity | OSCC | tissue remodeling | 84/7305 | 175/18723 | 9.39e-03 | 3.36e-02 | 84 |
GO:00703716 | Oral cavity | OSCC | ERK1 and ERK2 cascade | 150/7305 | 330/18723 | 9.47e-03 | 3.38e-02 | 150 |
GO:003103217 | Oral cavity | OSCC | actomyosin structure organization | 93/7305 | 196/18723 | 9.63e-03 | 3.41e-02 | 93 |
GO:00442625 | Oral cavity | OSCC | cellular carbohydrate metabolic process | 130/7305 | 283/18723 | 9.98e-03 | 3.49e-02 | 130 |
GO:00463301 | Oral cavity | OSCC | positive regulation of JNK cascade | 46/7305 | 89/18723 | 1.01e-02 | 3.50e-02 | 46 |
GO:0032526 | Oral cavity | OSCC | response to retinoic acid | 54/7305 | 107/18723 | 1.04e-02 | 3.54e-02 | 54 |
GO:0045453 | Oral cavity | OSCC | bone resorption | 35/7305 | 65/18723 | 1.07e-02 | 3.64e-02 | 35 |
GO:004620915 | Oral cavity | OSCC | nitric oxide metabolic process | 42/7305 | 81/18723 | 1.27e-02 | 4.24e-02 | 42 |
GO:00703724 | Oral cavity | OSCC | regulation of ERK1 and ERK2 cascade | 140/7305 | 309/18723 | 1.34e-02 | 4.46e-02 | 140 |
GO:00454298 | Oral cavity | OSCC | positive regulation of nitric oxide biosynthetic process | 23/7305 | 40/18723 | 1.36e-02 | 4.50e-02 | 23 |
GO:19055175 | Oral cavity | OSCC | macrophage migration | 30/7305 | 55/18723 | 1.39e-02 | 4.59e-02 | 30 |
GO:0032770 | Oral cavity | OSCC | positive regulation of monooxygenase activity | 20/7305 | 34/18723 | 1.51e-02 | 4.91e-02 | 20 |
GO:004325426 | Oral cavity | EOLP | regulation of protein-containing complex assembly | 112/2218 | 428/18723 | 1.58e-16 | 1.35e-13 | 112 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa05170 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa05163 | Colorectum | AD | Human cytomegalovirus infection | 75/2092 | 225/8465 | 2.00e-03 | 1.10e-02 | 7.01e-03 | 75 |
hsa051351 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa051701 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa051631 | Colorectum | AD | Human cytomegalovirus infection | 75/2092 | 225/8465 | 2.00e-03 | 1.10e-02 | 7.01e-03 | 75 |
hsa051352 | Colorectum | SER | Yersinia infection | 43/1580 | 137/8465 | 2.15e-04 | 2.10e-03 | 1.52e-03 | 43 |
hsa046702 | Colorectum | SER | Leukocyte transendothelial migration | 37/1580 | 114/8465 | 2.77e-04 | 2.56e-03 | 1.86e-03 | 37 |
hsa051702 | Colorectum | SER | Human immunodeficiency virus 1 infection | 58/1580 | 212/8465 | 1.08e-03 | 8.56e-03 | 6.21e-03 | 58 |
hsa051632 | Colorectum | SER | Human cytomegalovirus infection | 57/1580 | 225/8465 | 7.40e-03 | 3.84e-02 | 2.79e-02 | 57 |
hsa049122 | Colorectum | SER | GnRH signaling pathway | 27/1580 | 93/8465 | 9.68e-03 | 4.72e-02 | 3.43e-02 | 27 |
hsa051353 | Colorectum | SER | Yersinia infection | 43/1580 | 137/8465 | 2.15e-04 | 2.10e-03 | 1.52e-03 | 43 |
hsa046703 | Colorectum | SER | Leukocyte transendothelial migration | 37/1580 | 114/8465 | 2.77e-04 | 2.56e-03 | 1.86e-03 | 37 |
hsa051703 | Colorectum | SER | Human immunodeficiency virus 1 infection | 58/1580 | 212/8465 | 1.08e-03 | 8.56e-03 | 6.21e-03 | 58 |
hsa051633 | Colorectum | SER | Human cytomegalovirus infection | 57/1580 | 225/8465 | 7.40e-03 | 3.84e-02 | 2.79e-02 | 57 |
hsa049123 | Colorectum | SER | GnRH signaling pathway | 27/1580 | 93/8465 | 9.68e-03 | 4.72e-02 | 3.43e-02 | 27 |
hsa051356 | Colorectum | FAP | Yersinia infection | 43/1404 | 137/8465 | 1.21e-05 | 1.62e-04 | 9.86e-05 | 43 |
hsa046706 | Colorectum | FAP | Leukocyte transendothelial migration | 37/1404 | 114/8465 | 2.12e-05 | 2.53e-04 | 1.54e-04 | 37 |
hsa049126 | Colorectum | FAP | GnRH signaling pathway | 28/1404 | 93/8465 | 8.16e-04 | 5.14e-03 | 3.13e-03 | 28 |
hsa051636 | Colorectum | FAP | Human cytomegalovirus infection | 55/1404 | 225/8465 | 1.42e-03 | 7.67e-03 | 4.67e-03 | 55 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTK2B | SNV | Missense_Mutation | | c.2871N>A | p.Met957Ile | p.M957I | Q14289 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD |
PTK2B | SNV | Missense_Mutation | rs750561555 | c.553N>T | p.Arg185Trp | p.R185W | Q14289 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A3XS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
PTK2B | SNV | Missense_Mutation | | c.973N>C | p.Glu325Gln | p.E325Q | Q14289 | protein_coding | tolerated(0.24) | benign(0.044) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PTK2B | SNV | Missense_Mutation | | c.1817G>T | p.Ser606Ile | p.S606I | Q14289 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTK2B | SNV | Missense_Mutation | | c.1681N>C | p.Glu561Gln | p.E561Q | Q14289 | protein_coding | tolerated(0.06) | benign(0.006) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PTK2B | insertion | In_Frame_Ins | novel | c.2331_2332insCGGTGTCCCATGGTCCTATATTTGTTCTCAAGGAAATGCCTG | p.His777_Ser778insArgCysProMetValLeuTyrLeuPheSerArgLysCysLeu | p.H777_S778insRCPMVLYLFSRKCL | Q14289 | protein_coding | | | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PTK2B | insertion | Frame_Shift_Ins | novel | c.789_790insGTCATAGATC | p.Thr264ValfsTer8 | p.T264Vfs*8 | Q14289 | protein_coding | | | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
PTK2B | insertion | Frame_Shift_Ins | novel | c.2148_2148+1insGTAAGCCAAGCCATGT | p.Pro717ValfsTer10 | p.P717Vfs*10 | Q14289 | protein_coding | | | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PTK2B | SNV | Missense_Mutation | novel | c.1757G>A | p.Arg586His | p.R586H | Q14289 | protein_coding | deleterious(0) | possibly_damaging(0.854) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PTK2B | SNV | Missense_Mutation | rs773709584 | c.2779N>A | p.Leu927Ile | p.L927I | Q14289 | protein_coding | tolerated(1) | benign(0) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2185 | PTK2B | DRUGGABLE GENOME, KINASE, ION CHANNEL, G PROTEIN COUPLED RECEPTOR, TYROSINE KINASE, ENZYME | | PMID27774822-Compound-Figure10Example1 | | |
2185 | PTK2B | DRUGGABLE GENOME, KINASE, ION CHANNEL, G PROTEIN COUPLED RECEPTOR, TYROSINE KINASE, ENZYME | | Imidazo[4,5-c]pyridine derivative 1 | | |
2185 | PTK2B | DRUGGABLE GENOME, KINASE, ION CHANNEL, G PROTEIN COUPLED RECEPTOR, TYROSINE KINASE, ENZYME | | Aminotriazolopyridine derivative 1 | | |
2185 | PTK2B | DRUGGABLE GENOME, KINASE, ION CHANNEL, G PROTEIN COUPLED RECEPTOR, TYROSINE KINASE, ENZYME | | CID 94381 | CHEMBL374632 | |
2185 | PTK2B | DRUGGABLE GENOME, KINASE, ION CHANNEL, G PROTEIN COUPLED RECEPTOR, TYROSINE KINASE, ENZYME | | HTS-05058 | CHEMBL261692 | |
2185 | PTK2B | DRUGGABLE GENOME, KINASE, ION CHANNEL, G PROTEIN COUPLED RECEPTOR, TYROSINE KINASE, ENZYME | | PMID27774824-Compound-Figure11Example1up | | |
2185 | PTK2B | DRUGGABLE GENOME, KINASE, ION CHANNEL, G PROTEIN COUPLED RECEPTOR, TYROSINE KINASE, ENZYME | | TCMDC-125185 | CHEMBL580819 | |
2185 | PTK2B | DRUGGABLE GENOME, KINASE, ION CHANNEL, G PROTEIN COUPLED RECEPTOR, TYROSINE KINASE, ENZYME | inhibitor | CHEMBL3137331 | DEFACTINIB | |
2185 | PTK2B | DRUGGABLE GENOME, KINASE, ION CHANNEL, G PROTEIN COUPLED RECEPTOR, TYROSINE KINASE, ENZYME | | PF-04965842 | ABROCITINIB | |
2185 | PTK2B | DRUGGABLE GENOME, KINASE, ION CHANNEL, G PROTEIN COUPLED RECEPTOR, TYROSINE KINASE, ENZYME | | ASP-015K | PEFICITINIB | |